Induction chemotherapy increases efficacy and survival rate of patients with locally advanced esophageal squamous cell carcinoma

被引：2

作者：

Huang, Yuting ^{[1
,2
]}

Chang, Jing ^{[1
]}

Guo, Xiaolei ^{[1
]}

Zhang, Chao ^{[3
]}

Ji, Wenping ^{[4
]}

Zhou, Shusheng ^{[1
]}

Wang, Chao ^{[1
]}

Zhang, Xu ^{[2
,5
]}

机构：

[1] Anhui Med Univ, Dept Oncol, Chaohu Hosp, Chaohu, Peoples R China

[2] Anhui Med Univ, Dept Oncol, Affiliated Hosp 1, Hefei, Peoples R China

[3] Anhui Med Univ, Dept Neonatol, Chaohu Hosp, Chaohu, Peoples R China

[4] Anhui Med Univ, Dept Sci Res, Chaohu Hosp, Chaohu, Peoples R China

[5] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

基金：

中国国家自然科学基金; 中国博士后科学基金;

关键词：

esophageal cancer; concurrent chemoradiotherapy; induction chemotherapy; prognosis; survival; DEFINITIVE CHEMORADIOTHERAPY; SECONDARY ANALYSIS;

D O I：

10.3389/fonc.2022.1067838

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ObjectiveThe efficacy of concurrent chemoradiotherapy (CRT) after induction chemotherapy (IC) in the treatment of esophageal squamous cell carcinoma (ESCC) remains unclear. The purpose of this study was to explore the efficacy of IC in patients with ESCC. Methods124 patients with ESCC receiving CRT were included. Patients were divided into IC+CRT group and CRT group. Short-term and long-term efficacy as well as survival time of the two groups were compared, influencing factors of IC efficacy were investigated, and overall survival (OS) and progression-free survival (PFS) between the two groups were compared in different subgroups. ResultsThere was no significant difference in the objective response rate (ORR) between the two groups. After IC, the ORR was higher in patients with single-drug concurrent chemotherapy weekly and patients with effective IC. In the long-term efficacy, advanced clinical stage patients had a shorter PFS compared to early-stage patients, and chemoradiotherapy mode ameliorates patients' PFS. OS and PFS of IC+CRT group were longer than that of CRT group in both tumor diameter <5cm and single-drug chemotherapy weekly subgroups. In addition, OS of IC+CRT group was longer than that of CRT group in pathological grade G1-2 subgroup. ConclusionsIC improve the efficacy and survival rate of patients with locally advanced ESCC, and the benefits are more advantageous in subgroups of effective IC, pathological grade G1-2, tumor diameter < 5cm, single-drug concurrent chemotherapy weekly.

引用

页数：11